Condition
Biliary Tract Neoplasm
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Unknown2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02527824Phase 2UnknownPrimary
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
NCT01595217Not ApplicableCompletedPrimary
MRCP Diagnoses EHCC Better When Combined DWI
NCT02146703Phase 2CompletedPrimary
Gemcitabine and S-1 for Advanced Biliary Tract Cancer
NCT01542281Not ApplicableUnknown
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
Showing all 4 trials